GlassScriptPhysician profile
Inessa Y Meyerovich
NPI 1619957404
$11,084.88
in general payments reported to CMS, 2019-2025
40 companies · $3,225 in 2025
The $3,225 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $390 · 2021: $799 · 2022: $1,545 · 2023: $1,422 · 2024: $1,997 · 2025: $3,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,484 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,484.00 |
| Education | $159.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,799.48 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,511.65 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,301.99 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,147.04 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $679.41 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $641.29 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $522.09 | 2019-2025 | Fanapt |
| Alkermes, INC. | $496.34 | 2019-2025 | Aristada, Lybalvi |
| Aimmune Therapeutics, INC. | $431.36 | 2024-2025 | Zenpep |
| Neurocrine Biosciences, INC. | $400.19 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $200.67 | 2023-2025 | Auvelity |
| Harmony Biosciences LLC | $186.20 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.92 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $159.55 | 2019-2023 | Spravato |
| Nestle Healthcare Nutrition INC. | $149.42 | 2022-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148.45 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $139.99 | 2024-2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.20 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $94.16 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $83.12 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $67.58 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $65.47 | 2021 | |
| Bausch Health US, LLC | $52.38 | 2019-2025 | Aplenzin |
| Allergan, INC. | $52.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.04 | 2023-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $45.75 | 2025 | Farxiga, Airsupra |
| Almatica Pharma LLC | $41.18 | 2022 | |
| Lilly USA, LLC | $40.09 | 2020 | |
| Neuronetics, INC. | $34.15 | 2024 | Neurostar Tms Therapy System |
| Janssen Scientific Affairs, LLC | $30.74 | 2025 | Spravato |
| Indivior INC. | $25.43 | 2024 | Perseris |
| Corcept Therapeutics | $25.00 | 2025 | Korlym |
| Ardelyx, INC. | $23.90 | 2023 | Ibsrela |
| Exact Sciences Corporation | $22.73 | 2024 | Cologuard Collection Kit |
| Impel Pharmaceuticals INC. | $21.82 | 2023 | Trudhesa |
| Shire North American Group INC | $20.00 | 2019 | |
| Astellas Pharma US INC | $20.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $20.00 | 2020 | |
| Renalytix Ai, INC. | $19.16 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Amneal Pharmaceuticals LLC | $17.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inessa Meyerovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.